Royal Bank of Canada
LXEO icon

Royal Bank of Canada’s Lexeo Therapeutics LXEO Stock Holding History

Royal Bank of Canada’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30K Sell
5,300
-1,421
-21% -$10.1K ﹤0.01% 5721
2025
Q4 		$67K Sell
6,721
-128
-2% -$1.17K ﹤0.01% 5397
2025
Q3 		$46K Buy
6,849
+3,711
+118% +$17.9K ﹤0.01% 5856
2025
Q2 		$12K Buy
3,138
+1,305
+71% +$4.29K ﹤0.01% 6433
2025
Q1 		$6K Buy
1,833
+868
+90% +$3.85K ﹤0.01% 6307
2024
Q4 		$6K Sell
965
-2,188
-69% -$17.2K ﹤0.01% 6497
2024
Q3 		$28K Buy
3,153
+2,186
+226% +$26.1K ﹤0.01% 5978
2024
Q2 		$15K Buy
967
+616
+175% +$8.95K ﹤0.01% 6185
2024
Q1 		$6K Buy
+351
New +$5.49K ﹤0.01% 6385

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's LXEO Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lexeo Therapeutics (LXEO) stake by 21% in Q1 2026, selling an estimated $10.1K and leaving 5,300 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #5721.

Royal Bank of Canada first reported a position in LXEO in Q1 2024 and has held it in 9 quarters since. The position peaked at $67K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Royal Bank of Canada held 5,300 shares of Lexeo Therapeutics worth $30K as of Q1 2026.
  • Royal Bank of Canada sold 1,421 Lexeo Therapeutics shares in Q1 2026, an estimated $10.1K.
  • Lexeo Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5721 holding.
  • Royal Bank of Canada first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Royal Bank of Canada's Lexeo Therapeutics position peaked at $67K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.